HUE037287T2 - Pulzáló hatóanyagleadás - Google Patents

Pulzáló hatóanyagleadás

Info

Publication number
HUE037287T2
HUE037287T2 HUE11709763A HUE11709763A HUE037287T2 HU E037287 T2 HUE037287 T2 HU E037287T2 HU E11709763 A HUE11709763 A HU E11709763A HU E11709763 A HUE11709763 A HU E11709763A HU E037287 T2 HUE037287 T2 HU E037287T2
Authority
HU
Hungary
Prior art keywords
drug release
pulsatile drug
pulsatile
release
drug
Prior art date
Application number
HUE11709763A
Other languages
English (en)
Inventor
Alexander Mullen
Howard Stevens
Sarah Eccleston
Original Assignee
Univ Strathclyde
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Strathclyde filed Critical Univ Strathclyde
Publication of HUE037287T2 publication Critical patent/HUE037287T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/288—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Botany (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HUE11709763A 2010-03-05 2011-03-04 Pulzáló hatóanyagleadás HUE037287T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1003766.1A GB201003766D0 (en) 2010-03-05 2010-03-05 Pulsatile drug release

Publications (1)

Publication Number Publication Date
HUE037287T2 true HUE037287T2 (hu) 2018-08-28

Family

ID=42136598

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE11709763A HUE037287T2 (hu) 2010-03-05 2011-03-04 Pulzáló hatóanyagleadás

Country Status (13)

Country Link
US (1) US9474719B2 (hu)
EP (1) EP2542228B1 (hu)
JP (2) JP2013521332A (hu)
DK (1) DK2542228T3 (hu)
ES (1) ES2660544T3 (hu)
GB (2) GB201003766D0 (hu)
HU (1) HUE037287T2 (hu)
NO (1) NO2542228T3 (hu)
PL (1) PL2542228T3 (hu)
PT (1) PT2542228T (hu)
SI (1) SI2542228T1 (hu)
TR (1) TR201802596T4 (hu)
WO (1) WO2011107749A2 (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010325960C1 (en) 2009-12-02 2015-08-06 Adamas Pharma, Llc Amantadine compositions and methods of use
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
US8652527B1 (en) 2013-03-13 2014-02-18 Upsher-Smith Laboratories, Inc Extended-release topiramate capsules
US9101545B2 (en) 2013-03-15 2015-08-11 Upsher-Smith Laboratories, Inc. Extended-release topiramate capsules
CN105142618A (zh) * 2013-03-15 2015-12-09 韩国联合制药株式会社 提供药理及临床效应的莫沙必利每日单次施用缓释制剂
CN103271908B (zh) * 2013-05-23 2019-02-12 浙江华海药业股份有限公司 含有替米沙坦和苯磺酸氨氯地平的口服片剂及其制备方法
US10154971B2 (en) 2013-06-17 2018-12-18 Adamas Pharma, Llc Methods of administering amantadine
WO2015023675A2 (en) 2013-08-12 2015-02-19 Pharmaceutical Manufacturing Research Services, Inc. Extruded immediate release abuse deterrent pill
US9492444B2 (en) 2013-12-17 2016-11-15 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
US10172797B2 (en) 2013-12-17 2019-01-08 Pharmaceutical Manufacturing Research Services, Inc. Extruded extended release abuse deterrent pill
CA2955229C (en) 2014-07-17 2020-03-10 Pharmaceutical Manufacturing Research Services, Inc. Immediate release abuse deterrent liquid fill dosage form
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
JP2017531026A (ja) 2014-10-20 2017-10-19 ファーマシューティカル マニュファクチュアリング リサーチ サービシズ，インコーポレーテッド 徐放性乱用抑止性液体充填剤形
CN105640909B (zh) 2014-11-14 2019-09-20 正大天晴药业集团股份有限公司 一种含有达比加群酯的药用组合物
GB201420306D0 (en) * 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Compositions
GB201420311D0 (en) 2014-11-14 2014-12-31 Bio Images Drug Delivery Ltd Pharmaceutical processing
DK3261645T3 (da) 2015-02-27 2021-06-07 Dechra Ltd Stimulering af appetit, håndtering af vægttab og behandling af anoreksi hos hunde og katte
AU2016225052B2 (en) 2015-02-27 2021-07-08 Cingulate Therapeutics LLC Tripulse release stimulant formulations
TW201717919A (zh) * 2015-07-02 2017-06-01 國際藥品股份公司 雷諾多重壓縮錠劑
KR102203229B1 (ko) * 2016-01-08 2021-01-14 에리슨제약(주) 용출률이 개선된 네비보롤을 포함하는 약학적 조성물
CN109414423A (zh) 2016-04-08 2019-03-01 赛伦诺科技有限公司 包含丙戊酸的延迟释放药物制剂和其用途
WO2018001582A1 (en) 2016-06-30 2018-01-04 Interquim, S.A. Ranolazine multiple compressed tablets
KR101841355B1 (ko) * 2016-09-02 2018-03-22 영남대학교 산학협력단 D-싸이클로세린의 약제학적 제형 및 이의 제조방법
CN106619678A (zh) * 2016-11-17 2017-05-10 郑州郑先医药科技有限公司 一种治疗慢性咽炎的药物
WO2018145268A1 (zh) * 2017-02-08 2018-08-16 上海市第六人民医院 降压药在预防和治疗骨坏死中的应用
CN107412180B (zh) * 2017-06-17 2020-05-26 江西医学高等专科学校 一种帕利哌酮包芯片及其制备方法
IL272834B1 (en) 2017-08-24 2024-04-01 Adamas Pharma Llc Compositions of amantadine, their preparation, and methods of use
AU2018378348A1 (en) 2017-12-05 2020-06-18 Sunovion Pharmaceuticals Inc. Crystal forms and production methods thereof
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
US10799138B2 (en) 2018-04-05 2020-10-13 University Of Maryland, Baltimore Method of administering sotalol IV/switch
US20190381056A1 (en) 2018-06-17 2019-12-19 Axsome Therapeutics, Inc. Compositions for delivery of reboxetine
US10512620B1 (en) 2018-08-14 2019-12-24 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11610660B1 (en) 2021-08-20 2023-03-21 AltaThera Pharmaceuticals LLC Antiarrhythmic drug dosing methods, medical devices, and systems
US11696902B2 (en) 2018-08-14 2023-07-11 AltaThera Pharmaceuticals, LLC Method of initiating and escalating sotalol hydrochloride dosing
US11344518B2 (en) 2018-08-14 2022-05-31 AltaThera Pharmaceuticals LLC Method of converting atrial fibrillation to normal sinus rhythm and loading oral sotalol in a shortened time frame
US20200147093A1 (en) 2018-10-15 2020-05-14 Axsome Therapeutics, Inc. Use of esreboxetine to treat nervous system disorders such as fibromyalgia
US11020402B2 (en) 2018-10-15 2021-06-01 Axsome Therapeutics, Inc. Use of reboxetine to treat narcolepsy
WO2020212956A1 (en) * 2019-04-18 2020-10-22 Shivalik Rasayan Limited Oral composition of otilonium bromide
CA3142355A1 (en) 2019-06-04 2020-12-10 Sunovion Pharmaceuticals Inc. Modified release formulations and uses thereof
MX2019008467A (es) 2019-07-16 2019-11-07 Federico Amezcua Amezcua Combinacion sinergica de s-ketorolaco y pregabalina en una composicion farmaceutica para el tratamiento del dolor neuropatico.
CN110483788B (zh) * 2019-07-19 2021-11-05 中国地质大学（武汉） 一种MIL-53(Fe)复合材料及其制备方法和用于降解四环素的应用
CN110251677B (zh) * 2019-07-29 2021-04-13 牡丹江医学院 用于治疗肺纤维化的药物组合物及其应用
CN114302712B (zh) * 2019-09-04 2023-08-04 鲁南贝特制药有限公司 一种阿昔莫司多单元缓释微丸片及其制备方法
US11766419B2 (en) * 2021-01-08 2023-09-26 Banasthali Vidyapith Mebeverine as soluble epoxide hydrolase inhibitor
CN113499376A (zh) * 2021-07-16 2021-10-15 上海交通大学医学院附属瑞金医院卢湾分院 治疗顽固性失眠症的联合用药物及其应用

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8518301D0 (en) * 1985-07-19 1985-08-29 Fujisawa Pharmaceutical Co Hydrodynamically explosive systems
LU86099A1 (fr) 1985-09-30 1987-04-02 Pharlyse Formes galeniques a liberation prolongee du verapamil,leur fabrication et medicaments les contenant
US5145644A (en) 1990-12-20 1992-09-08 Allergan, Inc. Hydrogen peroxide destroying compositions and methods of making and using same
GB9117361D0 (en) 1991-08-12 1991-09-25 Euro Celtique Sa Oral dosage form
ES2106818T3 (es) 1991-10-30 1997-11-16 Glaxo Group Ltd Composicion multicapa que contiene antagonistas de histamina o secotina.
JPH07223970A (ja) * 1994-02-10 1995-08-22 Tanabe Seiyaku Co Ltd 消化管内適所放出製剤
US5558879A (en) 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
US5788987A (en) * 1997-01-29 1998-08-04 Poli Industria Chimica Spa Methods for treating early morning pathologies
US6312724B1 (en) 1997-04-04 2001-11-06 Isa Odidi Sustained release pharmaceutical matrix tablet of pharmaceutically acceptable salts of diclofenac and process for preparation thereof
CA2301883A1 (en) 1997-09-11 1999-03-18 Nycomed Danmark A/S Modified release multiple-units compositions of non-steroid anti-inflammatory drug substances (nsaids)
SE9704870D0 (sv) 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
WO2008079102A1 (en) 2005-05-10 2008-07-03 Elan Corporation, Plc Modified release loxoprofen compositions
US6632451B2 (en) 1999-06-04 2003-10-14 Dexcel Pharma Technologies Ltd. Delayed total release two pulse gastrointestinal drug delivery system
WO2000078292A1 (fr) * 1999-06-18 2000-12-28 Takeda Chemical Industries, Ltd. Preparations solides a desintegration rapide
EP1064937A1 (en) * 1999-06-28 2001-01-03 Sanofi-Synthelabo Timed dual release dosage forms comprising a short acting hypnotic or a salt thereof
ATE376826T1 (de) 2001-09-28 2007-11-15 Mcneil Ppc Inc Darreichungsformen zur modifizierten freisetzung
JP2005510477A (ja) 2001-10-08 2005-04-21 サン・ファーマシューティカル・インダストリーズ・リミテッド 抗痙攣薬の間隙をあけたドラッグデリバリーシステム
CN1674877A (zh) * 2002-06-07 2005-09-28 兰贝克赛实验室有限公司 控释的多单位药物释放系统
US20060177506A1 (en) 2003-03-17 2006-08-10 Shigeo Yanai Release control compositions
US20040241100A1 (en) * 2003-03-17 2004-12-02 Fabre Kramer Pharmaceutical, Inc. Nasally administrable compositions of zolpidem and methods of use
RU2391093C2 (ru) 2003-04-24 2010-06-10 Джаготек Аг Таблетка замедленного высвобождения с заданной геометрией ядра
JP4505859B2 (ja) * 2003-08-08 2010-07-21 味の素株式会社 ナテグリニド含有製剤
KR100782918B1 (ko) * 2003-09-19 2007-12-07 펜웨스트 파머슈티칼즈 컴파니 지연 방출성 제형
US20050152974A1 (en) 2003-12-31 2005-07-14 Garth Boehm Atomoxetine formulations
US20050220877A1 (en) 2004-03-31 2005-10-06 Patel Ashish A Bilayer tablet comprising an antihistamine and a decongestant
GB0423964D0 (en) * 2004-10-28 2004-12-01 Jagotec Ag Dosage form
WO2006093353A1 (ja) 2005-03-03 2006-09-08 Takeda Pharmaceutical Company Limited 放出制御組成物
US20070098788A1 (en) 2005-10-28 2007-05-03 Gore Subhash P Non-benzodiazepine hypnotic compositions
AR056633A1 (es) * 2005-12-07 2007-10-17 Gador Sa Composiciones farmaceuticas de agentes hipnoticos de accion corta en forma de liberacion modificada y los procedimientos para preparar dichas formulaciones
US9486446B2 (en) 2006-12-28 2016-11-08 Takeda Pharmaceutical Company Limited Orally disintegrating solid preparation
WO2008129517A2 (en) 2007-04-23 2008-10-30 Ranbaxy Laboratories Limited A stabilized delayed release pharmaceutical composition of rabeprazole
TW200914006A (en) * 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
WO2009101940A1 (ja) * 2008-02-11 2009-08-20 Dainippon Sumitomo Pharma Co., Ltd. 溶出性の改善された錠剤
US8240507B2 (en) 2008-06-20 2012-08-14 Graco Minnesota Inc. Seal-retaining valve for fluid metering device
TW201006473A (en) * 2008-08-13 2010-02-16 Orient Pharma Co Ltd Bi-layer medicine tablet containing Zaleplon
GB201003734D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Delayed prolonged drug delivery
GB201003731D0 (en) 2010-03-05 2010-04-21 Univ Strathclyde Immediate/delayed drug delivery

Also Published As

Publication number Publication date
PL2542228T3 (pl) 2018-07-31
EP2542228A2 (en) 2013-01-09
DK2542228T3 (en) 2018-03-05
JP6165824B2 (ja) 2017-07-19
EP2542228B1 (en) 2017-11-29
GB2491775A (en) 2012-12-12
JP2013521332A (ja) 2013-06-10
GB201003766D0 (en) 2010-04-21
GB201217619D0 (en) 2012-11-14
WO2011107749A2 (en) 2011-09-09
TR201802596T4 (tr) 2018-03-21
SI2542228T1 (en) 2018-05-31
NO2542228T3 (hu) 2018-04-28
JP2016040309A (ja) 2016-03-24
PT2542228T (pt) 2018-02-26
ES2660544T3 (es) 2018-03-22
US9474719B2 (en) 2016-10-25
US20130022676A1 (en) 2013-01-24
WO2011107749A3 (en) 2012-05-03

Similar Documents

Publication Publication Date Title
GB201217619D0 (en) Pulsatile drug release
IL226245A0 (en) History
EP2566334A4 (en) SOLID MEDIA FOR THE CONTROLLED RELEASE OF MEDICAMENTS
EP2489334A4 (en) MEDICAL ENDOPROTHESIS
EP2543405A4 (en) SYRINGE
GB201010193D0 (en) Medicinal use
SG10201507079WA (en) Syringe
HK1243004A1 (zh) 輸液製劑
GB201019354D0 (en) Prothesis
GB201017546D0 (en) Light inducing drug release
EP2554168A4 (en) PHARMACEUTICAL COMPOSITION WITH CONTROLLED RELEASE
ZA201301950B (en) Bvdv vaccine
GB201015822D0 (en) Medical ruggedised case
EP2564852A4 (en) MEDICAMENT TREATING CEREBRAL TUMORS
EP2564818A4 (en) MEDICAL ENDOPROTHESIS
PL2394638T3 (pl) Nowe połączenia farmaceutyczne
GB201012564D0 (en) Medical cast
HRP20141173T1 (hr) Medikament koji sadrži miramistin
HK1172255A1 (en) Extended release preparation
EP2524698A4 (en) INSULIN PRODUCTION
GB201006162D0 (en) Wheelchair
EP2668961A4 (en) PHARMACEUTICAL COMBINATION PREPARATION
GB201001335D0 (en) Drug release formulations
GB201016615D0 (en) Drug release composition
GB201001317D0 (en) Medicament